Curevo Vaccine Announces $26M Series A-1 Financing
SEATTLE-November 16, 2022 -(BUSINESS WIRE)–Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round. This brings total funding raised in 2022 to $86M for the…Read More
Read MoreSaluda Medical Adds Laureen DeBuono to Board of Directors
ARTARMON, Australia, Oct. 4, 2022 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, today announced the appointment of Laureen DeBuono to its board of directors and Chair of the company’s Audit Committee….Read More
Read MoreRivus Pharmaceutical Closes $132M Series B
CHARLOTTESVILLE, Va., September 22, 2022 – Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi…Read More
Read MoreArsenal Bio Closes $220M Series B
South San Francisco, Calif. – September 6, 2022 – Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round. New investors Softbank Vision Fund 2, Bristol-Myers Squibb Company, Byers…Read More
Read MoreRani Therapeutics Completes $45M Debt Financing
SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”, “the Company” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported positive topline results for the single-ascending portion of the Phase 1 clinical study of…Read More
Read More